Skip to main content

Advertisement

Springer Nature Link
Log in

Ultra-High Performance Liquid Chromatography–Mass Spectrometry for the Metabolomic Analysis of Urine in Colorectal Cancer

  • Original Article
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

We report here the results of a pilot study in which ultra-high performance liquid chromatography/time-of-flight–mass spectrometry (UPLC/TOF–MS) and multivariate statistical analysis (supervised partial least squares discriminant analysis, PLS-DA) were applied for urinary metabolite profiling and data interpretation. The results of the PLS-DA indicated that the metabolic pattern as a whole was significantly different between the groups of preoperative colorectal cancer (CRC) patients, postoperative CRC patients, and healthy volunteers, respectively. The preoperative group of patients showed significantly increased levels of low-molecular weight compounds (LMC) MW 283 and MW 234 in comparison to the group of healthy volunteers group. After the operation, the levels of these two LMC significantly decreased. These preliminary results suggest that the UPLC–MS-based method coupled with pattern recognition will likely lead to procedures with the potential to be clinically applicable for the diagnosis of CRC and, consequently, to an improvement in patient prognosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Hung KE, Chung DC. Colorectal cancer screening: today and tomorrow. South Med J. 2006;99(3):240–246. doi:10.1097/01.smj.0000203817.89741.29.

    Article  PubMed  Google Scholar 

  2. You WC, Jin F, Devesa S, et al. Rapid increase in colorectal cancer rates in urban Shanghai, 1972–97, in relation to dietary changes. J Cancer Epidemiol Prev. 2002;7(3):143–146.

    PubMed  Google Scholar 

  3. Moller Sorensen N, Vejgaard Sorensen I, Ornbjerg Wurtz S, et al. Biology and potential clinical implications of tissue inhibitor of metalloproteinases-1 in colorectal cancer treatment. Scand J Gastroenterol. 2008;43(7):774–786. doi:10.1080/00365520701878163.

    Article  CAS  Google Scholar 

  4. Lindon JC, Holmes E, Bollard ME, et al. Metabonomics technologies and their applications in physiological monitoring, drug safety assessment and disease diagnosis. Biomarkers. 2004;9(1):1–31. doi:10.1080/13547500410001668379.

    Article  CAS  PubMed  Google Scholar 

  5. Saghatelian A, Cravatt BF. Global strategies to integrate the proteome and metabolome. Curr Opin Chem Biol. 2005;9(1):62–68. doi:10.1016/j.cbpa.2004.12.004.

    Article  CAS  PubMed  Google Scholar 

  6. Griffin JL. Understanding mouse models of disease through metabolomics. Curr Opin Chem Biol. 2006;10(4):309–315. doi:10.1016/j.cbpa.2006.06.027.

    Article  CAS  PubMed  Google Scholar 

  7. Nobeli I, Thornton JM. A bioinformatician’s view of the metabolome. Bioessays. 2006;28(5):534–545. doi:10.1002/bies.20414.

    Article  CAS  PubMed  Google Scholar 

  8. Griffin JL, Bollard ME. Metabonomics: its potential as a tool in toxicology for safety assessment and data integration. Curr Drug Metab. 2004;5(5):389–398. doi:10.2174/1389200043335432.

    Article  CAS  PubMed  Google Scholar 

  9. A J, Trygg J, Gullberg J, et al. Extraction and GC/MS analysis of the human blood plasma metabolome. Anal Chem. 2005;77(24):8086–8094.

    Google Scholar 

  10. Thysell E, Pohjanen E, Lindberg J, et al. Reliable profile detection in comparative metabolomics. OMICS. 2007;11(2):209–224. doi:10.1089/omi.2007.0006.

    Article  CAS  PubMed  Google Scholar 

  11. Nicholson K, Lindon JC, Holm E. Metabonomics: understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica. 1999;29(11):1181–1189. doi:10.1080/004982599238047.

    Article  CAS  PubMed  Google Scholar 

  12. Griffin JL, Kauppinen RA. Tumour metabolomics in animal models of human cancer. J Proteome Res. 2007;6(2):498–505. doi:10.1021/pr060464h.

    Article  CAS  PubMed  Google Scholar 

  13. Beckonert O, Keun HC, Ebbels TM, et al. Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts. Nat Protocols. 2007;2(11):2692–2703. doi:10.1038/nprot.2007.376.

    Article  CAS  Google Scholar 

  14. Kind T, Tolstikov V, Fiehn O, et al. A comprehensive urinary metabolomic approach for identifying kidney cancerr. Anal Biochem. 2007;363(2):185–195. doi:10.1016/j.ab.2007.01.028.

    Article  CAS  PubMed  Google Scholar 

  15. Lu G, Wang JS, Zhao XJ, et al. Study on gender difference based metabolites in urine by ultra high performance liquid chromatography/time of flight mass spectrometry. Chin J Chromatogr. 2006;24(2):109–113. doi:10.1016/S1872-2059(06)60005-9.

    Article  CAS  Google Scholar 

  16. Wilson ID, Nicholson JK, Castro-Perez J, et al. High resolution “ultra performance” liquid chromatography coupled to oa-TOF mass spectrometry as a tool for differential metabolic pathway profiling in functional genomic studies. J Proteome Res. 2005;4(2):591–598. doi:10.1021/pr049769r.

    Article  CAS  PubMed  Google Scholar 

  17. Stanley EG, Bailey NJ, Bollard ME, et al. Sexual dimorphism in urinary metabolite profiles of Han Wistar rats revealed by nuclear-magnetic-resonance-based metabonomics. Anal Biochem. 2005;343(2):195–202. doi:10.1016/j.ab.2005.01.024.

    Article  CAS  PubMed  Google Scholar 

  18. Plumb RS, Granger JH, Stumpf CL, et al. A rapid screening approach to metabonomics using UPLC and oa-TOF mass spectrometry: application to age, gender and diurnal variation in normal/Zucker obese rats and black, white and nude mice. Analyst (Lond). 2005;130(6):844–849. doi:10.1039/b501767j. PMID: 10598751.

    Article  CAS  Google Scholar 

  19. Zheng YF, Xu GW, Liu DY, et al. Study of urinary nucleosides as biological marker in cancer patients analyzed by Micellar Electrokinetic Chromatography. Electrophoresis. 2002;23:4104–4109. doi:10.1002/elps.200290027.

    Article  CAS  PubMed  Google Scholar 

  20. Perroud B, Lee J, Valkova N. Pathway analysis of kidney cancer using proteomics and metabolic profiling. Mol Cancer. 2006;5:64. doi:10.1186/1476-4598-5-64.

    Article  PubMed  CAS  Google Scholar 

  21. Schmidt C. Metabolomics takes its place as latest up-and-coming “omic” science. J Natl Cancer Inst. 2004;96(10):732–734.

    Article  PubMed  Google Scholar 

  22. Dettmer K, Hammock BD. Metabolomics: A new exciting weld within the “omics” sciences. Environ Health Perspect. 2004;112:A396–A397.

    PubMed  Google Scholar 

  23. Wren SA. Peak capacity in gradient ultra performance liquid chromatography (UPLC). J Pharm Biomed Anal. 2005;38(2):337–343. doi:10.1016/j.jpba.2004.12.028.

    Article  CAS  PubMed  Google Scholar 

  24. Plumb R, Castro-Perez J, Granger J, et al. Ultra-performance liquid chromatography coupled to quadrupole-orthogonal time-of-flight mass spectrometry. Rapid Commun Mass Spectrom. 2004;18(19):2331–2337. doi:10.1002/rcm.1627.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

We also would like to express our deep and sincere gratitude to the Professor M. Michael Wolf (Boston University School of Medicine, USA) for his advice on this manuscript when he came to Shanghai. This work was financially supported by grants from the Shanghai Science and Technology Development Fund (No.05DJ14010) and the Major Basic Research Program of Shanghai (No. 07DZ19505).

Author information

Authors and Affiliations

  1. Department of Surgery, The Sixth People’s Hospital Affiliated to Shanghai Jiaotong University, 600 Yishan Road, Shanghai, 200233, China

    Yan-Lei Ma, Huan-Long Qin, Wei-Jie Liu, Jia-Yuan Peng & Long Huang

  2. Zhejiang Chinese Medical University, Hangzhou, 310053, China

    Xiao-Ping Zhao

  3. Pharmaceutical Information Institute, College of Pharmaceutial Sciences, Zhejiang University, Hangzhou, 310058, China

    Yi-Yu Cheng

Authors
  1. Yan-Lei Ma
    View author publications

    You can also search for this author inPubMed Google Scholar

  2. Huan-Long Qin
    View author publications

    You can also search for this author inPubMed Google Scholar

  3. Wei-Jie Liu
    View author publications

    You can also search for this author inPubMed Google Scholar

  4. Jia-Yuan Peng
    View author publications

    You can also search for this author inPubMed Google Scholar

  5. Long Huang
    View author publications

    You can also search for this author inPubMed Google Scholar

  6. Xiao-Ping Zhao
    View author publications

    You can also search for this author inPubMed Google Scholar

  7. Yi-Yu Cheng
    View author publications

    You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence to Huan-Long Qin.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ma, YL., Qin, HL., Liu, WJ. et al. Ultra-High Performance Liquid Chromatography–Mass Spectrometry for the Metabolomic Analysis of Urine in Colorectal Cancer. Dig Dis Sci 54, 2655–2662 (2009). https://doi.org/10.1007/s10620-008-0665-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-008-0665-4

Keywords